190 results on '"Feliciano, Josephine L."'
Search Results
2. Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses
3. First-line Osimertinib for Lung Cancer With Uncommon EGFR Exon 19 Mutations and EGFR Compound Mutations
4. Expanding Beyond Maximum Grade: Chemotherapy Toxicity over Time by Age and Performance Status in Advanced Non‐Small Cell Lung Cancer in CALGB 9730 (Alliance A151729)
5. Definitive Chemoradiation and Durvalumab Consolidation for Locally Advanced, Unresectable KRAS-mutated Non-Small Cell Lung Cancer
6. Unmet Needs, Quality of Life, and Financial Toxicity Among Survivors of Lung Cancer
7. Outpatient Embedded Palliative Care for Patients with Advanced Thoracic Malignancy: A Retrospective Cohort Study
8. Toxicity and survival outcomes in older adults receiving concurrent or sequential chemoradiation for stage III non-small cell lung cancer in Alliance trials (Alliance A151812)
9. Lung Cancer Survivorship: Physical, Social, Emotional, and Medical Needs of NSCLC Survivors
10. Clinician Perceptions of Barriers and Facilitators for Delivering Early Integrated Palliative Care via Telehealth
11. Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non–Small-Cell Lung Cancer
12. Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy
13. Pneumonitis in Non–Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors
14. Association of area‐level mortgage denial and guideline‐concordant non‐small‐cell lung cancer care and outcomes in the United States.
15. Improved lung cancer clinical outcomes in patients with autoimmune rheumatic diseases
16. Do older patients with non-small cell lung cancer also benefit from first-line platinum-based doublet chemotherapy? Observations from a pooled analysis of 730 prospectively-treated patients (Alliance Study A151622)
17. The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis
18. Hospitalization and definitive radiotherapy in lung cancer: incidence, risk factors and survival impact
19. Abstract 3374: Circulating cell-free tumor DNA dynamics capture minimal residual disease with neoadjuvant immune checkpoint blockade plus chemoradiotherapy for patients with operable esophageal/gastroesophageal junction cancer
20. Abstract 4483: Distinct spatial distribution patterns of ALK-inhibitor naïve versus ALK-inhibitor treated ALK-positive NSCLC brain metastases
21. Interventions for Breathlessness in Patients With Advanced Cancer
22. Real-World Outcomes and Prognostic Factors Among Patients with Advanced Non-Small Cell Lung Cancer and High PD-L1 Expression Treated with Immune Checkpoint Inhibitors as First-Line Therapy
23. Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy
24. Sex-specific differences in immunogenomic features of response to immune checkpoint blockade
25. Comparative “nocebo effects” in older patients enrolled in cancer therapeutic trials: Observations from a 446‐patient cohort
26. Disparities in Telemedicine Success and Their Association With Adverse Outcomes in Patients With Thoracic Cancer During the COVID-19 Pandemic
27. An Oncology Urgent Care Clinic for the Management of Immune-Related Adverse Events: A Descriptive Analysis
28. Abstract 1973: Patients with operable esophageal cancer and improved responses to combined chemoradiotherapy and immunotherapy display distinct microbiome profiles enriched in multiple Bacteroides species
29. Mutation status and postresection survival of patients with non–small cell lung cancer brain metastasis: implications of biomarker-driven therapy
30. Information Blocking and Oncology
31. Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC
32. Longitudinal Trends of Financial Toxicity in Patients With Lung Cancer: A Prospective Cohort Study
33. Cost-effectiveness of pembrolizumab + chemotherapy versus chemotherapy and pembrolizumab monotherapy in first line treatment of NSCLC in the US ��� updated analyses with additional trial follow-up
34. Cost-effectiveness of Pembrolizumab + Chemotherapy versus Chemotherapy and Pembrolizumab Monotherapy in 1st Line Treatment of NSCLC in the U.S. ��� updated analyses with additional trial follow-up
35. Association of severe lymphopenia and disease progression in unresectable locally advanced non-small cell lung cancer treated with definitive chemoradiation and immunotherapy
36. QIM21-090: The Expanding Role of an Oncology Urgent Care Clinic for the Management of Immune-Related Adverse Events
37. Pharmacologic Interventions for Breathlessness in Patients With Advanced Cancer
38. Nonpharmacological Interventions for Managing Breathlessness in Patients With Advanced Cancer
39. Additional file 1 of Hospitalization and definitive radiotherapy in lung cancer: incidence, risk factors and survival impact
40. Cost-effectiveness of pembrolizumab + chemotherapy versus chemotherapy and pembrolizumab monotherapy in first line treatment of NSCLC in the US – updated analyses with additional trial follow-up
41. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non–Small Cell Lung Cancer
42. Expanding Beyond Maximum Grade: Chemotherapy Toxicity over Time by Age and Performance Status in Advanced Non-Small Cell Lung Cancer in CALGB 9730 (Alliance A151729)
43. Patient‐reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial
44. Hospitalization and Definitive Radiotherapy in Lung Cancer: Incidence, Risk Factors and Survival Impact
45. Patient-reported outcome measures in definitive chemoradiation for non-small cell lung cancer
46. Cost–effectiveness of pembrolizumab versus chemotherapy as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in the USA
47. Cost-effectiveness of pembrolizumab+chemotherapy versus chemotherapy and pembrolizumab monotherapy in first line treatment of NSCLC in the US - updated analyses with additional trial follow-up.
48. Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the 1st-line treatment of squamous NSCLC in the U.S
49. Corrigendum to “Outcomes of patients with disease recurrence after treatment for locally advanced non-small cell lung cancer detected by routine follow-up CT scans versus a symptom driven evaluation” [Lung Cancer 135 (September) (2019) 16–20]
50. Outcomes of patients with disease recurrence after treatment for locally advanced non-small cell lung cancer detected by routine follow-up CT scans versus a symptom driven evaluation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.